CAS 717899-97-3

Formule : C24H22Cl2N6O3

InChI : InChI=1S/C24H22Cl2N6O3/c1-12(2)32-10-15(20-22(27)28-11-29-23(20)32)21(33)13-4-7-19(35-3)18(8-13)31-24(34)30-17-6-5-14(25)9-16(17)26/h4-12H,1-3H3,(H2,27,28,29)(H2,30,31,34)

Code InChI : VFCRSIORGUNNGT-UHFFFAOYSA-N

SMILES : CC(C)N1C=C(C2=C(N=CN=C21)N)C(=O)C3=CC(=C(C=C3)OC)NC(=O)NC4=C(C=C(C=C4)Cl)Cl

CE-245677

CAS : 717899-97-3

CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.

Formule : C₂₄H₂₂Cl₂N₆O₃

Degré de pureté : 98.99% - 99.23%

Couleur et forme : Solid

Masse moléculaire : 513.38

Ref: TM-T14921

Ce-245677

CAS : 717899-97-3

Formule : C₂₄H₂₂Cl₂N₆O₃

Degré de pureté : 99%

Masse moléculaire : 513.3759

Ref: IN-DA01JJTQ

CE-245677

CAS : 717899-97-3

CE-245677 is a tropomyosin-derived peptide hormone that has been shown to have potent platelet-derived growth factor (PDGF) receptor activation in vitro and in vivo. This compound is also able to activate the multikinase, which is an enzyme that controls cellular proliferation. CE-245677 has been shown to inhibit tumor vasculature growth and colorectal carcinoma cell growth. CE-245677 also has pharmacokinetic properties that are desirable for clinical development, including a short half-life and high clearance rate from the body.
CE-245677 is currently in Phase II clinical trials for pediatric use with activated platelets, as well as Phase I clinical trials for cancer indications.

Formule : C₂₄H₂₂Cl₂N₆O₃

Degré de pureté : Min. 95%

Masse moléculaire : 513.38 g/mol

Ref: 3D-SDB89997